Founded 7 years without income, 9 months loss exceeded 200 million, this interventional cardiovascular device company plans to IPO in Hong Kong stocks

Reporter | Guo Jingjing

At the same time, Baixinan Biologics is completing the confirmatory clinical trial of the second-generation Iberis®, and it is expected that the second-generation Iberis® will be approved by the National Medical Products Administration in the second quarter of 2023
.
The company currently plans to commercialize the second-generation Iberis®, a product under development for renal nerve blockade, in China, Japan and Europe
.
Accordingly, Baixinan Biologics has reached a strategic partnership with Terumo (stock code: 4543), a company listed on the Tokyo Stock Exchange, and will complete the first human clinical trial of the second-generation Iberis® in Japan.
It is planned to be randomized in the second half of 2021.
In a controlled clinical trial, the second-generation Iberis® is expected to be launched in Japan in 2025
.

Baixinan Biology stated that its future development strategy involves five aspects: one is to rapidly advance the clinical development and commercialization of products under research in the later stage; the second is to further enhance R&D capabilities and expand our product portfolio; the third is to expand manufacturing capabilities and establish internal sales.
And marketing team; fourth is to expand geographic coverage and global presence; fifth is to actively seek external cooperation, strategic investment and acquisition opportunities
.

What needs attention is the gradual promotion of the policy of "collection with quantity".
The degradable stent has not yet been collected in the country.
However, once the collection continues, it will inevitably affect the profits of related enterprises and have a great impact on the industry
.
In November 2020, the "first order" of the national procurement of coronary stents opened.
The price of the selected stent dropped from the original average price of 13,000 yuan to about 700 yuan, and the average price dropped by about 94.
6%.
At that time, the news caused A-share related companies.
The stock price fell
.

In this regard, Baixinan Biologics stated that the centralized procurement policy only applies to drug-eluting stent products and will not directly affect the pricing of fully degradable stent products
.
However, the company admits that if patients' willingness to use fully degradable stent products is materially and adversely affected, Baixinan Bio will be forced to change its pricing strategy, and the company's performance and financial performance will be materially and adversely affected
.